Citizens initiated coverage of Bicara Therapeutics (BCAX) with an Outperform rating and $31 price target The firm says the company’s ficerafusp alfa, in combination with pembrolizumab, has delivered “standout efficacy” in HPV-negative head and neck squamous cell carcinoma. The analyst says Bicara shares represent an attractive investment opportunity, with 40% potential downside in a bear case and 210% potential upside in a bull case.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target
- Maintaining a Buy on Bicara Therapeutics: De‑Risked Phase 3 Path for Ficerafusp Alfa Supports $40 Target and $2.2B Valuation
- Bicara Sets Phase 3 Path for Ficerafusp Alfa
- Bicara Therapeutics announces Phase 3 optimal dose of ficerafusp alfa
- Bicara Therapeutics initiated with a Buy at BTIG